http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H08502474-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-443 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 |
| filingDate | 1993-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1996-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H08502474-A |
| titleOfInvention | Tocolytic oxytocin receptor antagonist |
| abstract | (57) Abstract: Formula X-Y-Z-R 1 wherein, X is located at (I) or (II); W is hydrogen or acetate; Y is, -CO -, - SO 2 - , -CO (CH 2) m - or - (CH 2) m - a and; Z is, N, O, S, -CHR -, - CR = CH -, - CH =, - (CH 2) m - Or —CHCHOH—; R is hydrogen, C 1-5 alkyl or C 1-5 alkoxycarbonylamino or quinuclidinylaminocarbonylamino; R 1 is —CH 3 , —CH (CH 3 ). 2 , C 1-5 alkoxycarbonyl; aryl, heterocyclic lower cycloalkyl substituted with R 2 and / or R 3 , —NR 4 R 5 or —NCOR 6 ; R 2 is hydrogen, hydroxy, carboxyl , acetyl, nitro, halogen, mono -, di- - or tri C 1-3 alkyl, spin Cyclic indenyl, N- spiro-in Damping piperidinyloxy, [where R is as defined above] O-R, O-Het [where Het is imidazole, benzimidazole or azide bromide benzene], -COR 6, - (CH 2) m -NHCOR 7, - (CH 2) m NHCOOR 7, - (CH 2) m -NR 8 R 9, - (CH 2) m -NHCO- (CH 2) m R 7, - (CH 2) m -NHCO- CHR 7 R 7, - (CH 2) m -NHCO-CH = CHR 7, - (CH 2) m -CO-O-R 7, - (CH 2) m -CO -O- (CH 2) m R 7 , - (CH 2) m -CO-O-CHR 7 R 7, - (CH 2) m -CO-O-CH = CHR 7, -NHSO 2 R [where R is as defined above], NHSO 2 R 7, - ( CH 2) m -O-R 10, -SO 2 R 10 , —COR 11 , aryl lower alkyl, alkylsulfonylalkyl, alkylsulfonylalkylamino; R 3 is one or two hydrogens, hydroxyl or C 1-5 alkyl; R 4 is hydrogen, C 1-5 alkyl or C 6-10 cycloalkyl; R 5 is hydrogen or acetyl; R 6 is (A) or (B); R 7 is alkylcarbamate alkyl, substituted with R 12 . Is arylalkyl or heterocyclylalkyl, hydrogen, C 1-4 alkyl, NSO 2 R 12 or NHO—C 1-4 alkyl; R 8 is hydrogen or C 1-5 alkyl; R 9 is hydrogen or be a C 1-5 alkyl; R 10 is, -CH 3, alkaryl, alkaryl alkyl or azide bromide benzene; R 11 is, -CH 3, aralkyl or f Russian be heterocyclylalkyl; R 12 is hydrogen C 1-5 alkyl or C 1-5 alkoxy; m is a compound of an a] integer from 0 to 5. Such compounds are effective as oxytocin and vasopressin antagonists. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010513384-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010513385-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011111875-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013522165-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013075894-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8541585-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014024993-A1 |
| priorityDate | 1992-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 181.